Latest Breaking News On - Unified dyskinesia rating scale - Page 6 : comparemela.com

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease May 17, 2021 07:59 ET | Source: PharmaTher Holdings Ltd. PharmaTher Holdings Ltd. Vancouver, British Columbia, CANADA TORONTO, May 17, 2021 (GLOBE NEWSWIRE) PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a psychedelics biotech company, is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s Investigational New Drug (“IND”) application to proceed with a Phase 2 clinical trial to evaluate the safety, efficacy and pharmacokinetics of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease (“LID-PD”).   PharmaTher expects to begin enrolling patients in the Phase 2 clinical trial in Q3-2021. Assuming the Phase 2 clinical trial is positive, the Company will request a meeting with the FDA to discuss

Robert hauserScott shermanAlberto espayTorsten falkFabio chianelliPharmather holdings ltdUniversity of cincinnatiUniversity of south floridaCompany investigational new drugCompany or pharmatherDrug administrationUniversity of arizonaMother holdingsInvestigational new drugChief executive officerActive placebo controlled trial